Davanone is the signature furanoid sesquiterpene ketone associated with davana oil and one of the archive's clearest composition-defining aroma constituents. Live sources strongly support its identity, stereochemical handling, and dominant occurrence in Artemisia pallens oils, while direct biological evidence remains preclinical and is centered on cytokine-inhibition work in macrophages plus exploratory small-model neuroprotection research. For AromaForge, davanone is best described as a high-relevance davana marker with emerging preclinical mechanism data rather than a clinically validated active.
Chemical identity and composition
Public registry records split davanone into a generic unspecific PubChem entry and a stereochemically defined record used by The Good Scents Company and NIST-linked references. Because the AromaForge oil records already use the stereospecific davana-fragrance registry and because the accessible davana literature often discusses cis- and trans-davanone side by side, this entry uses CAS 20482-11-5 while explicitly acknowledging that generic davanone naming can blur multiple isomeric records. Within the archive, davanone appears at 50.64% in a 2025 davana GC/MS report and the related davana archive record places cis-davanone at 45.8%, reinforcing davanone chemistry as the dominant fingerprint of davana materials.
Aroma and practical use
- Use the recorded fruity, sweet, herbal, wine-like, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2021 Chemistry and Biodiversity paper reported cis-davanone at 53.0% in davana oil and found that both the whole oil and isolated cis-davanone inhibited lipopolysaccharide-induced TNF-alpha and IL-6 in primary macrophages.
This is the strongest directly attributable constituent-level pharmacology source located in this pass because it links identity, composition, isolation, and cytokine-inhibition results for davanone chemistry itself.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2022 Biochemical and Biophysical Research Communications paper tested cis-davanone, bicyclogermacrene, and cis-hydroxy-davanone in a Caenorhabditis elegans Parkinsonism model.
The paper supports early neuroprotective research interest in isolated davana sesquiterpenoids, but the abstract highlights bicyclogermacrene as the strongest reported performer.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 1999 study on davana growth stage reported davanone as the major constituent of davana oil and found that its proportion decreased as the crop advanced from full flower-head emergence to seed-set initiation.
This supports davanone as a harvest-timing and authenticity marker even though it is not a direct pharmacology study.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2007 supercritical-fluid chromatography paper reported near-100% optically pure enriched davanone isolated from natural davana oil after stereochemical characterization.
This source is important for identity handling because it addresses isolation integrity and optical purity of davanone from natural davana oil.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
The Good Scents Company davanone page reviewed in this pass lists no determined oral, dermal, or inhalation toxicity values and shows a placeholder-style recommendation of 'not for fragrance use' and 'not for flavor use' rather than a validated finished-product safety limit.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No constituent-specific IFRA category limit, human tolerability study, or phototoxicity warning for isolated davanone was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Because the strongest efficacy evidence remains preclinical, archive summaries should not translate davanone cytokine or small-model neuro findings into medical claims.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
reduction_of_lps_induced_pro_inflammatory_cytokines
In primary macrophages, isolated cis-davanone reduced lipopolysaccharide-induced TNF-alpha and IL-6 output without reported cytotoxicity at effective concentrations.
This experimental finding does not establish benefit, dose or safety in people using this blend.
possible_redox_and_proteostasis_relevance_in_small_animal_model
Davana sesquiterpenoid testing in a Caenorhabditis elegans Parkinsonism model supports exploratory neuro-model relevance for the constituent class, although the abstract emphasizes stronger effects for bicyclogermacrene than for cis-davanone.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- No human clinical study specific to isolated davanone was verified in this pass.
- Public safety sources reviewed here do not establish a constituent-specific dermal maximum or robust toxicology profile for isolated davanone.
- Generic davanone naming still overlaps with cis-specific registry records, so future archive normalization may need a deliberate parent-versus-isomer policy.
- Worker c8 search (2026-07-13): davanone (CAS 20482-11-5) is the principal constituent (40-55%) of davana oil (Artemisia pallens); davana oil itself is listed as IFRA-compliant/not on the IFRA Restriction list (51st Amendment), but no constituent-specific RIFM safety assessment, NESIL, or numeric dermal limit for isolated davanone was located. Prior dermal_limit_pct:2 was an unsupported placeholder and has been corrected to null.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.